Yuheng Pharmaceutical Co., Ltd. introduces Korean Baoning Pharmaceutical Co., Ltd. in the treatment of hypertension

Yuheng pharmaceutical shall pay the initial expenses of 400000 US dollars to Baoning company Yuheng pharmaceutical will pay the relevant expenses to Baoning company in each stage of applying for the clinical approval documents, obtaining the clinical approval documents, obtaining the production approval documents, and after the listing, with the total amount not exceeding 5 million US dollars Baoning group is a listed company in South Korea, whose business covers pharmaceutical, medical equipment, consumer goods, baby products and other businesses Baoning pharmaceutical is one of its main subsidiaries Kanarb non masatan is the original research drug of the company, which is used to treat hypertension In recent years, it has grown rapidly in the Korean market This cooperation is conducive to increasing the company's pharmaceutical varieties, improving the product structure, reducing the risk of huge R & D investment, and will have a positive impact on the company's operating revenue and performance Boryung Pharma Signs Deal with Chinese Drug Company for Its "Kanarb" KOREA IT TIMES (INFO@KOREAITTIMES.COM) SEOUL, KOREA - "Kanarb," a high blood pressure drug developed by Boryung Pharmaceutical Co., will be exported to China, the first such instance for a Korean-made medication     The company signed on January 9 a license-out contract with China's Harbin Gloria Pharmaceuticals at its head office in Seoul's downtown The Korean drug company will be paid US$5.4 million for the licensing fee within this month, with a steady income of at least $75.5 million for the next ten years   Kanarb (Fimasartan) has been one of the most successful drugs ever developed by a Korean pharmaceutical company It has been sold in 13 countries including Mexico, Brazil, and Russia worth $115 million With the latest licensing agreement with the Chinese company, the total export volume would be about $200 million   Yang Hongbing, president of Harbin Gloria, said, "In large-scale clinical tests, Kanarb has been proven more effective than any other globally recognized high blood pressure drugs We are confident it will be successful in the Chinese market too."   Kanarb won the approval by the food and drug authorities in September 2010 It has since been one of the most popular drugs, ranking No 1 in terms of sales among top-20 new drugs developed in Korea during the 15-year period between 1999 and 2013.